Absorption and efficacy of miconazole nitrate 0.25% ointment in infants with diaper dermatitis

Journal of Drugs in Dermatology, May, 2007 by Lawrence F. Eichenfield, Melissa L. Bogen

11. Dixon PN, Warin RP, English MP. Role of Candida albicans infection in napkin rashes. Br Med J. 1969;2:23-27.

12. Dixon PN, Warin RP, English MP. Alimentary Candida albicans and napkin rashes. Br J Dermatol. 1972;86:458.

13. Spraker MK, Gisoldi EM, Siegfried EC, et al. Topical miconazole nitrate ointment in the treatment of diaper dermatitis complicated by candidiasis. Cutis. 2006;77:113-130.

14. West DP, Worobec S, Solomon LM. Pharmacology and toxicology of infant skin. J Invest Dermatol. 1981;76:147-150.

15. Munro DD. Topical corticosteroid therapy and its effect on the hypothalamic-pituitary-adrenal axis. Dermatologica. 1976;152(suppl 1): 173-180.

16. Ointment for diaper dermatitis with candidiasis. Nurse Pract. 2006; 31:62.

17. Janniger CK, Thomas I. Diaper dermatitis: an approach to prevention employing effective diaper care. Cutis. 1993;52:153-155.

18. Drouhet E, Dupont B. In vitro antifungal activity of sertaconazole. Arzneimittelforschung. 1992;42:705-711.

19. Hawser S, Islam K. Comparisons of the effects of fungicidal and fungistatic antifungal agents on the morphogenetic transformation of Candida albicans. J Antimicrob Chemother. 1999;43:411-413.

20. Vanheule R, Adriaensen K, De Hauwere R, Van Cutsem J, De Cree J. Prevalence and treatment with miconazole of fungal skin infections in children and premature infants. Castellania. 1974;2:91-92.

21. MacKie RM, Scott E. Topical miconazole cream in infantile napkin dermatitis. Practitioner. 1979;222:124-126.

22. Concannon P, Gisoldi E, Phillips S, et al. Diaper dermatitis: a therapeutic dilemma. Results of a double-blind placebo controlled trial of miconazole nitrate 0.25%. Pediatr Dermatol. 2001;18:149-155.

23. Vusion [package insert]. Princeton, NJ: Barrier Therapeutics; 2006.

24. Abrams LS, Weintraub HS. Disposition of radioactivity following intravaginal administration of [.sup.3.H]-miconazole nitrate. Am J Obstet Gynecol. 1983;147:970-971.

25. Brugmans J, Van Cutsem J, Heykants J, et al. Systemic antifungal potential, safety, biotransport and transformation of miconazole nitrate. Eur J Clin Pharmacol. 1972;5:93-99.

26. Tuck S. Neonatal systemic candidiasis treated with miconazole. Arch Dis Child. 1980;55:903-906.

27. Lewi PJ, Boelaert J, Daneels R, et al. Pharmacokinetic profile of intravenous miconazole in man: comparison of normal subjects and patients with renal insufficiency. Eur J Clin Pharmacol. 1976;10:49-54.

28. Sung JP, Grendahl JG, Levine HB. Intravenous and intrathecal miconazole therapy for systemic mycoses. West J Med. 1977;126:5-13.

29. Karnes TH, Shiu G, Shah VP Validation of bioanalytical methods. Pharm Res. 1991;8:421-426.

ADDRESS FOR CORRESPONDENCE

Lawrence F. Eichenfield MD

Rady Children's Hospital San Diego

8010 Frost Street Suite 602

San Diego, CA 92123-4204

Phone: 858-576-1700 ext. 4825

e-mail: TVBECK@CHSD.org

Lawrence F. Eichenfield MD, (a) Melissa L. Bogen ELS (b)

a. Rady Children's Hospital-San Diego and University of California San Diego, San Diego, CA

b. Fission Communications, New York, NY